Jerry Lewandowski provides consultation to healthcare and life sciences clients and their counsel regarding economic, regulatory, damages, information technology, and electronic discovery issues. In particular, his expertise relates to designing and executing sophisticated but efficient solutions to complex financial and economic questions by acquiring, assimilating, and analyzing electronic data from healthcare company and transactional computer systems, survey data, market data, and other data sources.
Mr. Lewandowski has extensive experience advising a wide array of clients in high-profile class action lawsuits, qui tam litigation, multidistrict litigation, and government investigations related to issues such as fraud, contract compliance, medical coding, pricing and billing practices, government pricing and reporting, sales and marketing practices, pharmacy practice issues, and government and commercial reimbursement. His healthcare clients have included managed care organizations, pharmaceutical manufacturers, pharmacy benefit managers, pharmacies (including specialty pharmacy), medical supply companies, clinical labs, and hospitals.
College of William & Mary
BBA, Accounting, 1996
BRG experts have worked on engagements for hospitals or health providers involved in disputes over reimbursement rates for both contracted and non-contracted services.
BRG experts assisted outside counsel for a global pharmaceutical company accused of fraudulent promotion of several of its products for indications that were not Food and Drug Administration approved (so-called “off-label” uses).
Bankruptcy courts have appointed BRG experts as conservator, special monitor, and trustee for managed healthcare plans undergoing liquidation or reorganization.
A pharmaceutical manufacturer retained BRG personnel in relation to a Department of Justice investigation with a central allegation that the manufacturer misstated its best price and underpaid Medicaid rebate.
BRG experts have assisted a number of pharmaceutical manufacturers and their outside counsel with disputes related to allegedly fraudulent and inflated average wholesale prices for drugs in the so-called “AWP matters.”
News & Insights
- BRG white paperApril 2019
News & Commentary
- AHLAJune 30, 2015
- Press ReleaseJuly 13, 2010
American Health Lawyers Association
Business Partners Board, Mason School of Business at the College of William and Mary